walk with Thanks, And X. down a start I'll slide P&L, quick Yeah. on is QX Joe. which the
the the revenue growth on we to organic mean X% line acquisitions quarter. organic adjusted housekeeping, we top about impact currency so basis some a constant divestitures, and talk First growth, and remove of when in of
revenue million a absorbed considering quarter $XX pretty growth, As of versus growth QX of we the XXXX. good seventh of Joe LOE drag assets organic said, from consecutive
and the the up of strength Rx our large in X% Four segment X% Russia, grew continued by International up International part East. by in X% Global LUMIFY of the on ramp sub-segments Revenue led Middle the organically in on organically B&L the posted B&L five business, business, within our quarter. growth in Consumer followed Canada, organically
ONEday Next, of up Vision the lenses strength Care our monthly plus was our the daily silicone X% overall our Biotrue outside and AQUALOX on family, our Japan. United hydrogel in in and States, hydrogel in Global ramp lenses, U.S. the lens XX% X% business ULTRA silicone
Elite organically Next, X% Global on Surgical strength up from was related our and system Stellaris consumables.
in to B&L finally in revenue LOTEMAX perspective, from our of segment a business X% Diversified of suspension declined authorized And revenue lost our wrap-up LOTEMAX U.S., organically, generic erosion our own to the in branded shows including our Global mainly due that to the segment. business OpthoRx greater up generics the
So in versus million International organically, $XX said, of which quarter overall, quarter. QX Salix XX% Joe to that of in TRULANCE XX% rates you terrific the break and XXXX. up star XXXX. for for up in was the XIFAXAN B&L solid The a components as I revenue the of quarter, think important the excludes segment. it's want delivered again about down XX% XIFAXAN as growth QX how But into another
impact volume, net XX% more meaning increase gross implemented the of part to January with our So from we we as to a in sold, the balance plus the for XIFAXAN. versus back from the QX the of as of X% that result that X% units XXXX initiatives XX% XIFAXAN of and Project took nets came price CORE improve growth came successful
CORE so XXXX enhancement falls perspective net in XIFAXAN prices and selling driven results, revenue for clearly roughly it Project a cost stands XIFAXAN in enhancement. half step in Reminder, optimization continue think is increase on of into of the function From and realized XIFAXAN. revenue as future category. in for growth growth the CORE durable a This will
items gross by reductions in the more process value XXXX. to half is While not other real results, transitory, repeating very net but in XXXX driven in
of more of if a by growth prospects driven number XXX about which XXXX. I've couple gross will Growth repeat, is be I'll forms XIFAXAN's selling price in said combination volume, we public units raise selling when price. a in of basis perhaps net what a points increase and the thinking selling
XIFAXAN XXXX, growth XXXX not will expect and should the to at safety seeing be important in XXXX. deliver sales attractive levels in tip, an So, at you net that versus would you're growth while rate I
more expected in the more that's strong to due I'm revenue on losses this quarter shift on quarter selling prices. from pronounced subject, of sees net one an resulting that our mix before substantial in QX in While I deterioration brand of GLUMETZA accelerated call mentioned that about channel performance we
So, the brand as you we've of half think about XXXX. in QX three GLUMETZA, the be rate of seen quarters may for run the what first
accounted revenue total PLENVU deliver for Ortho the million guided TRx XXXX. notes, positive track in $XX to $XX the and revenue for more revenue and quarter and we of TRULANCE growth remains systems, On In to not on of declines delivered delivered of the overcome RELISTOR medical XX% for our million could segment in derm Derm segment, feeds demand organically for XX% tips. strong business. Global as in continued in our down consumable Solta FLX turn FLX which on Solta demand Thermage growth was organic growth
And Hart Solta delivering in Asia Pac. and to other Europe. we to we opportunities to his growth, robust team allocating has ahead Solta to Western regions, mainly pursue XXXX, similar enable been be in as will resources look Tom more particularly
Medical for $XX of ACANYA. by $XX Our and the ZOVIRAX, million QX -- ELIDEL, militated of XXXX, versus was SOLODYN, LOEs million impact down Derm business
want Medical quarter growth Derm sales With others. a BRYHALI, the plus our return to ALTRENO Derm that per the net million brands, of ONEXTON, including and LOEs portfolio including with and tail and be SILIQ, RETIN-A MICRO, promoted $XX poised JUBLIA, ELIDEL, brands to to DUOBRII, of roughly TARGRETIN, CLINDAGEL, at will I $XX Medical to be QX, rebased XXXX reflected million now call quarter of results, the business bulk of out for in our in impact
versus Finally, QX our few team. I Diversified that pretty segment assets approximately declined good XXXX, X% point of a out that’s highlights. an were want call Barb quarter and for basis organically, considering drag to Purcell LOE XXX a her
access neuro QX franchise our Aplenzin of effective collaboration XL Wellbutrin grew as with including in business Spurr. in XXXX result versus the of team led and promotion Bob targeted Buproprion by Our a market and XX%
unit Our the branded of beneficiary of the those has LOEs of products been brands. selling generic our of and many versions authorized launching generics
were QX up XXXX. revenues of versus X% Generic
cash diversified of from but expected that maximize comes over We Now, flows I've before, basket the a said this to manage to assets it the here group time. long-term again. decline are
and job doing team and Our thereby objective maximize our to the great is slow that decline is a there. cash flow
a Down blended the me points XX.X% plus line, with XX quarter, gross XXXX. -- at in we basis gross excuse margin of were margin versus the QX of
year drove XXXX, sales Salix. the decreased a gross XX.X%. we gross than of gross XX Our majority a in the the and decreased year-to-date chain supply segment gross segment a generics the margin are of XX% with gross segment making where and in percentage Ortho point half to percentage greater point the positive improvement made margins of diversified for variance margin core full the Solto the roughly XXX in roughly initiatives Salix, Mix, up improved margins revenues. Note that total greater within basis B&L International Derm guiding was our basis in margin
Selling, additional advertising promotion in in drive constant with increased resources from revenue with and by the that and International International roughly acquisition sales addition the in and B&L and of and by Half expenses $XX million due movement promotional X% was our promotion XXXX currency. unfavorable QX came reported X% unfavorable of to compared deploying the associated advertising the Surgical Salix mainly businesses. growth TRULANCE. $XX million The of of was mainly to Vision due XXX selling increase Global Care territories and to
to increased investment X%, out up IT was spending G&A due building Company-wide infrastructure. mainly our
growth R&D our we million of $XX the to QX to increased and as portfolio to enable continue our compared in with long-term us organic adding R&D XXXX process businesses. Our the projects organization investment building of of sustain our for development
million QX in reported on and Our XXXX. up the Good quarter. basis X% on adjusted was currency with quarter compared $XXX of a EBITDA X% constant of a
going on the X, X, covered of them the details additional Slides X on each. to X I'm main and dwell items note segments, show not I've as for So
our from $XXX amount to cash to aligned million well while by of the XXXX. deliver amount is activities prior cash activities. from us slide cash million provided $XX turn $X.X The $X.X in In summary. operations the we billion up million cash prior operating year. down quarter the Year-to-date of year keeps slightly between generated So XX from from in the quarter, operating and flow
to you balance summary. If slide the sheet XX flip
note September of revolving quarter, we credit borrowings to the to revolving $XX of more million at allocate we During XX, to flow long-term we've reduced debt million cash TRULANCE. acquisition reduce million by XXXX. Year-to-date repaid paid our to want debt of of high-value roughly $XXX repaid could the credit term our as in million and view $XXX we business and what but borrowings loan activity September XX, zero case $XXX elected year-to-date mainly million. to long-term to repaid this have that $XXX I debt development
$XX million and and On raised increasing full revised range guidance. the we to million. top midpoint August XXXX billion The year the guidance $XX guidance. our from new tightened from the of by the August range $XX million slide The $X.XXX current Today, to our revenue midpoint billion. of XX for our guidance up $X.XXX our end the revenue by is low-end is guidance in of
the increase peso in As and part LOE the date business. part base our on forecast by the XXXX change you'll raise was which reduced the movements guidance XH significant unfavorable to assets for Offset million our $XX revenue FX million. $XX by revenue on driven million anticipated about see most for LOE since in August, slide with in in increase our $XX in moving for bridge by the XX, expectations
$X from that's million and and items. current $X to guidance million for revenue our million revenue $XX from plus and million R&D minus guidance. FX, We increased midpoint the the assets $XX came of our our improved, greater is raised plus billion margins million gross base from came $X.X The -- EBITDA -- adjusted other expectations a plus LOE for that for from to higher-than-expected also combination the $X.X tightened FX $XX of of guidance up investment $XX in from billion. August business
thing Last back it I turn Joe. before to
from expect million. increase was XXXX. in looking of I movements comes the of our $XX we by million at the more February. of unfavorable end At billion, guidance FX. current $X.X acquisition to back $XX think of roughly $XXX of offset revenue expected it's the for we guidance million Midpoint worth midpoint revenue revenue our million of in $XX revenue from range, the and plus XXXX million guidance from LOE TRULANCE our $XX how from back so now $X.XX in assets, expected initial with billion compared
The nets originally million. in forecast. than $XX increase So that million our performance the from explains Project businesses comes first better remaining base in businesses better and we driven gross $XX some by both Core to
constant Joe. a XXXX. degree was is That's for revenue the our story original the date tight of that up to point you we we've guidance to LOEs to improved to basis end how and proud We're currency which uncertain expect on the The accuracy. of our back excluding forecast quite
